ABSTRACT

Chronic Obstructive Pulmonary Disease (COPD) is becoming the second leading cause of death in the world where 80% of deaths are reported from low and middle-income countries. COPD is a chronic disease of high prevalence in younger as well as older people majorly due to smoking, air pollution, long-term exposure to harmful gases, and other comorbidities. COPD with other comorbidities are frequent among patients of internal medicine part, and usually, these patients are more drug dependents. Certain COPD medications, such as ?2-agonists, antimuscarinic compounds, methylxanthines, and other combinational medicines, are considered high risk due to their involvement in ended with adverse events. Above all ?2-agonists are the first choice of medication to treat COPD. However, the efficacy of the drug is the link between the potential benefits and risks. Considering the side effects of COPD patients, it is necessary to develop appropriate drug management. Drug management is a complicated process that involves specific knowledge, techniques, and methodologies to identify risks and mitigate them with a proper action plan. Timely reporting of adverse drug reactions is required to minimize the chances of risk to patients and the healthcare system. So, Health care professionals need to bring new practices for pharmacovigilance in COPD. Keywords: Beta2-agonists, Chronic Obstructive Pulmonary Disease (COPD), Adverse Drug Reactions (ADR), Pharmacovigilance, Nasal Patches
Publication date: 01/07/2023

https://ijbpas.com/pdf/2023/July/MS_IJBPAS_2023_7322.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.7.7322